Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK worldwide. The intense itch associated with the condition can lead to sleeping disorders, anxiety and depression. There is no cure as of today. The current treatments can ameliorate the symptoms…. Read more »
New publication
Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide Authors: Aleksandra Dondalska, Elin Rönnberg, Haisha Ma, Sandra Axberg Pålsson, Elin Magnusdottir, Tianle Gao, Lucille Adam, Ethan A. Lerner , Gunnar Nilsson, Malin Lagerström and Anna-Lena Spetz Front. Immunol., 30 September 2020 https://doi.org/10.3389/fimmu.2020.559589
TIRmed Pharma receives approval to grant patents in Europe
TIRmed Pharma receives approval of patent in the US
TIRmed Pharma´s proprietary compound to treat inflammatory skin disorders was issued patent approval in the US, April 21st, 2020.
TIRmed Pharma receives SME Instrument Phase 1 grant from EU Grant No 885787-TIR-C
In Dec, 2019 TIRmed Pharma was awarded funding from the European Union´s Horizon 2020 research and innovation progamme under grant agreement number 885787-TIR-C regarding the development of a cream to treat immune responses in atopic dermatitis.
Nordic Life Science Days 2018
TIRmed Pharma is presenting at the Nordic Life Science Days on September 10th, 2018 at Stockholm Waterfront